KRAS and familial pancreatic carcinoma: KRAS, CDKN2A, TP53, and SMAD4 are known to be commonly altered in pancreatic cancer [36] while KRAS mutation has been proposed as a biomarker in cfDNA for the detection of PDAC [35].